2,7-bis((4-(tert-butyl)piperidin-1-yl)sulfonyl)anthracene-9,10-dione

• 分子结构分类: 有机化合物 - 苯类化合物 - 蒽
• 英文名称: 2,7-bis((4-(tert-butyl)piperidin-1-yl)sulfonyl)anthracene-9,10-dione
• 英文别名: 2,7-Bis[(4-tert-butylpiperidin-1-yl)sulfonyl]anthracene-9,10-dione
• 化学式: C₃₂H₄₂N₂O₆S₂
• 分子量: 614.827
• InChiKey: ALNUXGOGHPTIRP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.1
• 重原子数：
  42
• 可旋转键数：
  6
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  126
• 氢给体数：
  0
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  2,7-bis((4-(tert-butyl)piperidin-1-yl)sulfonyl)anthracene-9,10-dione 在 吡啶 、 盐酸羟胺 作用下， 反应 16.0h， 以60.2%的产率得到2,7-bis((4-(tert-butyl)piperidin-1-yl)sulfonyl)anthracene-9,10-dione dioxime
  参考文献：
  名称：

  Design, Synthesis, and Biological Evaluation of a Series of Anthracene-9,10-dione Dioxime β-Catenin Pathway Inhibitors

  摘要：

  The Wnt/beta-catenin signaling pathway plays a vital role in cell growth, the regulation, cell development, and the differentiation of normal stem cells. Constitutive activation of the Wnt/beta-catenin signaling pathway is found in many human cancers, and thus, it is an attractive target for anticancer therapy. Specific inhibitors of this pathway have been keenly researched and developed. Cell based screening of compounds library, hit-to-lead optimization, computational and structurebased design strategies resulted in the design and synthesis of a series of anthracene-9,10-dione dioxime series of compounds demonstrated potent inhibition of beta-catenin in vitro (IC50 < 10 nM, 14) and the growth of several cancer cell lines. This article discusses the potential of inhibiting the Wnt/beta-catenin signaling pathway as a therapeutic approach for cancer along with an overview of the development of specific inhibitors.

  DOI：

  10.1021/acs.jmedchem.5b00460
• 作为产物：
  描述：

  4-叔丁基哌啶 、 9,10-dioxo-9,10-dihydroanthracene-2,7-disulfonyl dichloride 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 4.0h， 生成 2,7-bis((4-(tert-butyl)piperidin-1-yl)sulfonyl)anthracene-9,10-dione
  参考文献：
  名称：

  Design, Synthesis, and Biological Evaluation of a Series of Anthracene-9,10-dione Dioxime β-Catenin Pathway Inhibitors

  摘要：

  The Wnt/beta-catenin signaling pathway plays a vital role in cell growth, the regulation, cell development, and the differentiation of normal stem cells. Constitutive activation of the Wnt/beta-catenin signaling pathway is found in many human cancers, and thus, it is an attractive target for anticancer therapy. Specific inhibitors of this pathway have been keenly researched and developed. Cell based screening of compounds library, hit-to-lead optimization, computational and structurebased design strategies resulted in the design and synthesis of a series of anthracene-9,10-dione dioxime series of compounds demonstrated potent inhibition of beta-catenin in vitro (IC50 < 10 nM, 14) and the growth of several cancer cell lines. This article discusses the potential of inhibiting the Wnt/beta-catenin signaling pathway as a therapeutic approach for cancer along with an overview of the development of specific inhibitors.

  DOI：

  10.1021/acs.jmedchem.5b00460

文献信息

• Design, Synthesis, and Biological Evaluation of a Series of Anthracene-9,10-dione Dioxime β-Catenin Pathway Inhibitors
  作者：Raffaella Soldi、Stephen K. Horrigan、Marek W. Cholody、Janak Padia、Venkataswamy Sorna、Jared Bearss、Glynn Gilcrease、Kapil Bhalla、Anupam Verma、Hariprasad Vankayalapati、Sunil Sharma

  DOI：10.1021/acs.jmedchem.5b00460

  日期：2015.8.13

  The Wnt/beta-catenin signaling pathway plays a vital role in cell growth, the regulation, cell development, and the differentiation of normal stem cells. Constitutive activation of the Wnt/beta-catenin signaling pathway is found in many human cancers, and thus, it is an attractive target for anticancer therapy. Specific inhibitors of this pathway have been keenly researched and developed. Cell based screening of compounds library, hit-to-lead optimization, computational and structurebased design strategies resulted in the design and synthesis of a series of anthracene-9,10-dione dioxime series of compounds demonstrated potent inhibition of beta-catenin in vitro (IC50 < 10 nM, 14) and the growth of several cancer cell lines. This article discusses the potential of inhibiting the Wnt/beta-catenin signaling pathway as a therapeutic approach for cancer along with an overview of the development of specific inhibitors.